drugset / Trial / NCT01713361

Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

NCT01713361

Phase 2 Completed 315 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is: * To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of bleeding and VTE, in patients undergoing total knee arthroplasty. * To compare the efficacy and safety profile of ISIS-FXIRx in patients who achieve less than or equal to 0.2 U/mL FXI activity levels to that of enoxaparin.

Timeline

Start
2012-10
Primary completion
2014-05
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject ISIS 416858 Antisense oligonucleotide 200 mg Subcutaneous
Subject ISIS 416858 Antisense oligonucleotide 300 mg Subcutaneous